The independent source for health policy research, polling, and news.
141-160 of 1,313 results
The percentage of people who say they鈥檝e tried to end a pregnancy without medical assistance increased after "Roe v. Wade" was overturned. One of the most common reasons for seeking a self-managed abortion was privacy concerns.
For the 2024 campaign, Joe Biden is out, and Kamala Harris is in. As the vice president makes moves toward the top of the Democratic presidential ticket, health policy is resurging as a campaign issue. Meanwhile, Congress tries 鈥 and again fails 鈥 to make timely progress on the annual government spending bills as abortion issues cause delays. Alice Miranda Ollstein of Politico, Stephanie Armour of 51视频 Health News, and Rachel Cohrs Zhang of Stat join 51视频 Health News鈥 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Anthony Wright, the new executive director of Families USA, about his plans for the organization and his history working with Harris on health topics.鈥
Even as part of a popular South Dakota tourist attraction, an independent pharmacy serving locals, remote ranchers, and sightseers struggles with staffing and insurer payments.
Louisiana lawmakers have added two drugs commonly used in pregnancy and reproductive health care to the state鈥檚 list of controlled dangerous substances, a move that has alarmed doctors in the state.
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
If she grabs the baton from President Joe Biden to become the new presumptive Democratic presidential nominee, Kamala Harris would widely be expected to take an aggressive stance in support of abortion access 鈥 hitting former President Donald Trump on an issue that could undermine his chances of victory.
A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation 鈥 with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law 鈥 could leave the country with a patchwork of disparate health regulations.
A debate marked by President Joe Biden鈥檚 faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
The Supreme Court has dismissed a challenge to the FDA鈥檚 approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of 51视频 Health News, and Emmarie Huetteman of 51视频 Health News join 51视频 Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews 51视频 president and CEO Drew Altman about 51视频鈥檚 new 鈥淗ealth Policy 101鈥 primer.
President Joe Biden is campaigning for reelection on his efforts to cut costs for Medicare patients at the pharmacy counter. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
51视频 Health News gives readers a chance to comment on a recent batch of stories.
51视频 Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here鈥檚 a collection of their appearances.
June is when the Supreme Court typically issues rulings in the major cases it hears during that year鈥檚 term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, 51视频鈥檚 Laurie Sobel, associate director for women鈥檚 health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
A disconnect between two federal programs meant to help keep hospitals afloat discourages struggling rural facilities from accepting the aid.
51视频 Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
51视频 Health News and California Healthline staffers made the rounds on national and local media in the last couple of weeks to discuss topical stories. Here鈥檚 a collection of their appearances.
As billions of dollars from settlements with opioid manufacturers and distributors go to state and local governments, efforts to reduce the epidemic鈥檚 harm can be hamstrung by drug paraphernalia laws. Health authorities say distributing clean syringes to users can save lives, but in states like Pennsylvania, it may be illegal.
漏 2026 51视频